AstraZeneca and Heptares Therapeutics enter licensing agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Heptares Therapeutics entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist HTL-1071, a small molecule immuno-oncology candidate.

AstraZeneca will focus on exploring HTL-1071 and any additional compounds across a range of cancers, including in combination with its existing portfolio of immunotherapies.

The companies will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

Heptares will receive an upfront payment of $10 million and is eligible to receive additional milestone payments based on agreed pre-clinical and clinical events. Subject to successful completion of development and commercialization milestones, Heptares is also eligible to receive more than $500 million as well as royalty payments.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login